gms | German Medical Science

61st Annual Meeting of the German Society of Neurosurgery (DGNC) as part of the Neurowoche 2010
Joint Meeting with the Brazilian Society of Neurosurgery on the 20 September 2010

German Society of Neurosurgery (DGNC)

21 - 25 September 2010, Mannheim

Association of the CC genotype of the regulatory Bcl-2 promoter polymorphism (-938C>A) with better 2-year survival in patients with glioblastoma multiforme

Meeting Abstract

  • Nicolai El Hindy - Abteilung für Neurochirurgie, Universität Duisburg-Essen, Essen, Deutschland
  • Hagen S. Bachmann - Institut für Pharmakogenetik, Universität Duisburg-Essen, Essen, Deutschland
  • Nicole Lambertz - Abteilung für Neurochirurgie, Universität Duisburg-Essen, Essen, Deutschland
  • Ulrich Sure - Abteilung für Neurochirurgie, Universität Duisburg-Essen, Essen, Deutschland
  • Winfried Siffert - Institut für Pharmakogenetik, Universität Duisburg-Essen, Essen, Deutschland
  • I. Erol Sandalcioglu - Abteilung für Neurochirurgie, Universität Duisburg-Essen, Essen, Deutschland

Deutsche Gesellschaft für Neurochirurgie. 61. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC) im Rahmen der Neurowoche 2010. Mannheim, 21.-25.09.2010. Düsseldorf: German Medical Science GMS Publishing House; 2010. DocV1540

DOI: 10.3205/10dgnc017, URN: urn:nbn:de:0183-10dgnc0174

Published: September 16, 2010

© 2010 El Hindy et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.en). You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.


Outline

Text

Objective: Bcl-2 plays a key role in the downregulation of apoptosis and proliferation, as well as increased chemoresistance in glioblastoma multiforme (GBM). We investigated the role of a common regulatory single-nucleotide polymorphism (-938C>A) which is located in the inhibitory P2 promoter of Bcl-2.

Methods: 160 patients suffering from GBM were retrospectively investigated. Inclusion criteria were availability of DNA and for patients still alive a follow-up of at least 24 months. The results were evaluated with respect to the basic clinical data, type of surgical intervention (gross total resection versus biopsy), adjuvant therapy, MGMT-promoter methylation as well as survival at the 2-year follow-up.

Results: At the two-year follow-up 127 (79.4%) of the 160 patients had died. Kaplan-Meier curves revealed a significantly higher rate of survival for homo- and heterozygous C-allele carriers (p=0.031). In the gross total resection subgroup the survival rate was 47.1% for homozygous C-allele carriers, 32.0% for heterozygous C-allele carriers, but only 21.4% for homozygous A-allele carriers (p=0.024). The stereotactic-biopsy subgroup showed no genotype-dependent differences. Multivariable Cox regression identified the Bcl-2 (-938AA) genotype as an independent negative prognostic factor for 2-year survival in the gross total resection subgroup according to the Bcl-2 (-938CC) genotype reference group (hazard ratio, 2.5; 95% CI, 1.1–5.5; p=0.022).

Conclusions: These results suggest the (-938C>A) polymorphism as a survival prognosticator as well as a marker for a high-risk group within patients with GBM and gross total resection.